Drug intelligence / Profile preview

plp10

Development stage: Unknown
Lead developer: Aniva International
Administration: Oral

Overview

PLP10 is a patented nutraceutical formula containing a specific combination of omega-3 and omega-6 fatty acids along with vitamins (γ-Tocopherol and β-carotene). It was developed as a dietary supplement primarily for multiple sclerosis patients. Clinical trials have shown it can significantly reduce relapse rates and slow disability progression in relapsing-remitting multiple sclerosis when used as an adjuvant to interferon-β treatment, without significant side effects.

Brand names: Neuroaspis plp10
Other names: NEUROASPIS plp10NEUROASPIS® plp10

Beyond the preview

Go deeper on plp10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on plp10.

Explore the full profile